Cytokinetics Announces Upcoming Presentations at the 2022

SOUTH SAN FRANCISCO, Calif., Sept. 26, 2022 (GLOBE NEWSWIRE) — Cytokinetics, Incorporated (Nasdaq: CYTK) today announced six upcoming presentations, including two presentations at the HCM Society’s 2022 inaugural Scientific Sessions, those newly instituted by the HCM Society Experts will be delivered at the Medical Society in National Harbor, MD, on September 30, 2022, and four presentations will be made at the Heart Failure Society of America (HFSA) Annual Scientific Meeting, to be held September 30, 2022 through October 3, 2022 in Washington, DC , takes place.

New data from REDWOOD-HCM OLE (Randomized Erating of Dosing Wwith CK-274 in Ostructive Odrain Dchill out HCM OPen Label Extension) will be presented in two Late Breaking Clinical Trial presentations, including one at the HCM Society 2022 Scientific Meetings on background cessation of standard medical therapy and one at the HFSA Annual Scientific Meeting on symptom improvement.

HCM Society Scientific Sessions 2022

Late Breaking Clinical Trials Session

title: Withdrawal of standard medical therapy in patients with obstructive hypertrophic cardiomyopathy treated with Aficamten in REDWOOD HCM OLE
moderator: Ahmad Masri, MD, Assistant Professor of Medicine, Department of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University
date: September 30, 2022
session title: Late Breaking Trials
session time: 10:30 a.m. – 10:40 a.m. ET
location: Westin National Port

Poster presentation

title: Implications for the quality of life of patients with obstructive hypertrophic cardiomyopathy
date: September 30, 2022
location: Westin National Port

Annual scientific meeting of the HFSA

Late Breaking Clinical Trial Session

title: Improvement in KCCQ scores in patients with obstructive hypertrophic cardiomyopathy treated with Aficamten in the REDWOOD-HCM OLE study
moderator: Sara Saberi, MD, Assistant Professor, Cardiovascular Medicine, Frankel Cardiovascular Center, University of Michigan Health
date: October 2, 2022
session title: Late Breaking Clinical Trials Session II
session time: 9:45am – 10:45am ET
presentation time: 10:15 – 10:25 a.m. ET
location: Potomac A/B

Also Read :  S. Korean activists clash with police over anti-Kim balloons

poster presentations

title: Efficacy and safety of Aficamten in patients with symptomatic obstructive hypertrophic cardiomyopathy: interim results of the randomized evaluation of dosing of CK-3773274 in hypertrophic cardiomyopathy (REDWOOD-HCM) open-label extension (OLE) study
moderator: Ahmad Masri, MD, Assistant Professor of Medicine, Department of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University
date: October 1, 2022
session title: Oral poster session II
poster number: 352
session time: 12:00 p.m. – 1:00 p.m. ET
location: Exhibition Hall, Oral Poster Theater

title: Safety, Efficacy, and Quantitative Understanding of Obstruction, Effects of Aficamten in hypertrophic cardiomyopathy (SEQUOIA-HCM) Study design: A phase 3 study
moderator: Caroline Coats, Ph.D., Clinical Senior Lecturer, School of Cardiovascular & Metabolic Health, University of Glasgow
date: October 1, 2022
session title: General Poster Consideration Session II
poster number: CTC-001
session time: 12:45 p.m. – 1:00 p.m. ET
location: Exhibition Hall ePoster Hub, Monitor 3

title: Prevalence and increased risk of hospitalization for heart failure with reduced ejection fraction
moderator: Nihar R. Desai, MD, MPH, Associate Professor of Medicine, Associate Director, Cardiovascular Medicine, Yale School of Medicine, Center for Outcomes Research and Evaluation
date: October 1, 2022
session title: General Poster Consideration Session III
poster number: 211
session time: 5:45 p.m. – 6:00 p.m. ET
location: Exhibition Hall ePoster Hub, Monitor 21

Also Read :  School of Medicine announces updated research leadership roles

About cytokinetics

Cytokinetics is a late-stage biopharmaceutical company focused on the discovery, development and commercialization of first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is impaired and/or declining . As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically designed to affect muscle function and contractility. Cytokinetics is preparing a US NDA filing omecamtiv mecarbil, its novel myocardial activator, following positive results from GALACTIC-HF, a large, international Phase 3 clinical trial in heart failure patients. Cytokinetics is conducting METEORIC-HF, a second Phase 3 clinical study omecamtiv mecarbil. Cytokinetics also develop aficamten, a next-generation cardiac myosin inhibitor, for the potential treatment of hypertrophic cardiomyopathies (HCM). The Company announced positive top-line results from Cohorts 1 and 2 in REDWOOD-HCM, a Phase 2 clinical trial aficamten in patients with obstructive HCM. Cytokinetics expects to start a phase 3 clinical trial aficamten in patients with obstructive HCM in Q4 2021. Cytokinetics are also developing relative, a rapid skeletal muscle troponin activator, currently the subject of COURAGE-ALS, a Phase 3 clinical trial in patients with ALS. Cytokinetics continues its 20+ year history of pioneering innovations in muscle biology and related pharmacology focused on disorders of muscle dysfunction and muscle weakness.

For more information about Cytokinetics, visit and follow us on Twitter, LinkedIn, Facebook and YouTube.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intention or obligation to update these forward-looking statements and claims the protection of the Safe Harbor statute for forward-looking statements. Examples of such statements include, but are not limited to, statements regarding our other clinical studies, statements regarding the potential benefits of omecamtiv mecarbil, aficamten, or any of our other drug candidates. research and development activities of Cytokinetics; the design, timing, results, significance and utility of pre-clinical and clinical results; and the characteristics and potential benefits of Cytokinetics’ other drug candidates. Such statements are based on management’s current expectations, however, actual results could differ materially due to various risks and uncertainties, including but not limited to potential difficulties or delays in development, testing, regulatory approvals to commence the study, progress or Cytokinetics’ product sales or manufacture or production of drug candidates that could slow or prevent clinical development or product approval; Cytokinetics’ drug candidates may have adverse side effects or insufficient therapeutic efficacy; the FDA or foreign regulatory authorities may delay or limit Cytokinetics’ ability to conduct clinical trials; Cytokinetics may not be able to obtain or maintain patents or trade secrets for its intellectual property; Standards of care may change, rendering Cytokinetics’ drug candidates obsolete; and competing products or alternative therapies may be developed by others for the treatment of indications targeted by Cytokinetics’ drug candidates and potential drug candidates. For more information on these and other risks related to Cytokinetics’ business, investors should consult Cytokinetics’ filings with the Securities and Exchange Commission.

Also Read :  GOP abortion ban would mean a nationwide crisis – WIZM 92.3FM 1410AM

CYTOKINETICS® and the CYTOKINETICS and the C-shape logo are registered trademarks of Cytokinetics in the US and certain other countries.

Diana Weiser
Senior Vice President, Corporate Communications, Investor Relations
(415) 290-7757

Source link